Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05671965
Other study ID # PFI-X
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 27, 2023
Est. completion date April 2024

Study information

Verified date March 2024
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this project is to investigate the effect of xylitol (given as pre-load), compared to sucrose, Ace-K, and water on energy intake during a subsequent ad libitum test meal in healthy participants. Furthermore, the release of GI hormones, glycemic control, appetite-related sensations, GI tolerance, sweetness and liking in response to the pre-loads will be investigated.


Description:

The subjects will participate in four study days. The screening will last 60 minutes, the study days about 4.5 hours each. After a simple-carbohydrate standard dinner, the subjects have to do an overnight fast until the next morning. Subjects will receive fixed equisweet doses of sucrose (33.5g), xylitol (33.5g), Ace-K (0.1675g), or water as oral pre-loads in a blinded, randomized (counterbalanced) fashion (t = -15 min). Fifteen minutes after the administration (t = 0 min), a standard solid test meal will be presented and ad libitum energy intake will be measured. The end of the test meal will be after 20 minutes or as soon as the subject stops eating for more than 5 minutes. Blood samples (to measure: glycemic control and GI hormones) will be collected at t = -16, t = -1, t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 min and appetite-related sensation rating will be collected at t = -16, t = -1, t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 min. GI symptoms and nausea are assessed at t = -16, -1, 30, 60, 120 and 180 min. At t = -10 min subjects are asked to rate the perceived sweetness and liking of the pre-load and at t = 180 min the perceived liking of the test meal.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date April 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy normal weight participants (10 male and 10 female) with a body-mass index (BMI) of 19.0-24.9 kg/m2 - Age 18-55 years - Stable body weight (± 5%) for at least three months - Able to give informed consent as documented by signature Exclusion Criteria: - Fructose intolerance - Pre-existing diet (vegetarian, vegan, sugar free, no breakfast) - Pre-existing regular consumption of xylitol and/or Ace-K (> 1/week) - Chronic or clinically relevant acute infections/diseases - Regular intake of medications, except contraceptives - Pregnancy: although no contraindication, pregnancy might influence metabolic state. - Substance abuse (more than 1 glass wine/beer per day; consumption of cannabis, cocaine, heroin, etc.) - Shift worker - Participation in another study with investigational drug within the 30 days preceding and during the present study

Study Design


Intervention

Dietary Supplement:
Xylitol
33.5g xylitol dissolved in 300mL tap water.
Sucrose
33.5g sucrose dissolved in 300mL tap water.
Acesulfame Potassium
0.1675g Ace-K dissolved in 300mL tap water.
Water
300mL tap water.

Locations

Country Name City State
Switzerland St. Claraspital Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of xylitol on energy intake during a subsequent ad libitum test meal Fifteen minutes after the administration of the pre-loads (t = 0 minutes), a standard solid test meal will be presented and ad libitum energy intake will be measured. Total energy intake will be measured from t = 0 until t = 20 minutes or as soon as the as the subject stops eating for more than 5 minutes.
Secondary Effects on GI hormone response - GLP-1 GLP-1 will be quantified using a non-radioactive highly sensitive sandwich ELISA (MSD V-PLEX - #K1503PD) in the presence of a chemiluminescent substrate. Blood will be drawn at the following time points :t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - PYY PYY-3-36 will be quantified using a non-radioactive high sensitive sandwich ELISA (Millipore - # EZHPYYT66K). Blood will be drawn at the following time points :t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - CCK Plasma cholecystokinin (CCK) levels will be measured with a sensitive radioimmunoassay using a highly specific antiserum (No. 92128) Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on GI hormone response - ghrelin Octanoylated ghrelin will be measured by a radioimmunoassay with 125I [Tyr24] human ghrelin [1-23] as tracer and a rabbit antibody against human ghrelin [1-8] (final dilution 1/100000), which does not cross-react with desoctanoylated ghrelin. Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma glucose Glucose will be measured by a glucose oxidase method (Rothen Medizinische Laboratorien AG, Basel, Switzerland). Blood will be drawn at the following time points: t = -16, t = -1 (before administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma insulin Insulin will be quantified using a chemiluminescent microparticle immunoassay (chemiflex) reagent kit (#8k41; Abbott) and the relative light units detected by the ARCHITECT optical system (model: CI4100; Abbott). Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma c-peptide C-peptide will be measured with a commercially available sandwich ELISA kit from Millipore (Millipore - # EZHCP-20K). Blood will be drawn at the following time points: t = -16, t = -1 (before administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on glycemic control - plasma glucagon Glucagon concentrations in plasma will be measured after extraction of plasma with 70% ethanol (vol/vol, final concentration). The antibody is directed against the C-terminus of the glucagon molecule (antibody code no. 4305) and therefore mainly measures glucagon of pancreatic origin. Blood will be drawn at the following time points: t = -16, t = -1 (before the administration of the pre-load), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-load).
Secondary Effects on appetite-related sensations Appetite perceptions (feelings of: a) hunger, b) satiety) are assessed by visual analogue scale (VAS). Visual analogue scales consist of a horizontal, unstructured, 10-cm line representing the minimum (0.0 points) to the maximum rating (10.0 points). Subjects assign a vertical mark across the line to indicate the magnitude of their subjective sensation at the present time point. The measurement is quantified by the distance from the left end of the line (minimum rating) to the subject's vertical mark. Visual analogue scales will be recorded at the following time points: t = -16, t = -1 (before the administration of the pre-loads), t = 15, t = 30, t = 60, t = 90, t = 120, t = 150, t = 180 minutes (after the administration of the pre-loads).
Secondary Effects on GI tolerance GI symptoms will be assessed by use of a checklist including the following questions: abdominal pain, nausea, vomiting, diarrhea, borborygmic, abdominal distension, eructation and increased flatus. GI tolerance will be recorded at t = -16, -1 (before the administration of the pre-load), 30, 60, 120 and 180 minutes (after the administration of the pre-load).
Secondary Sweetness of pre-load Sweetness is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Sweetness of the pre-load will be recorded at t = -10 minutes.
Secondary Liking ot the pre-load Liking is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Liking of the pre-load will be recorded at t = -10 minutes.
Secondary Liking of the test meal Liking is assessed by gLMS. General Labeled Magnitude Scales consist of an unequal, vertical line, which is marked with quasi-logarithmic verbal anchors describing different intensities (e.g. "strongest imaginable", "barely detectable"). Participants are instructed to place a mark on the line where their perceived intensity of sensation lies. Liking of the test meal will be recorded at t = 180 minutes.
See also
  Status Clinical Trial Phase
Completed NCT04219189 - The Acute Effect of Vaping on Food Intake N/A
Completed NCT02957318 - Effect of Potato Fiber on Appetite and Fecal Fat Excretion N/A
Completed NCT04378374 - The Effect of Pulse Flours on Blood Glucose, Satiety and Food Intake N/A
Completed NCT01199770 - Pasta Formulations, Portion Sizes and Their Effect on Appetite N/A
Recruiting NCT05443347 - Activity, Adiposity, and Appetite in Adolescents 2 Intervention N/A
Withdrawn NCT02111486 - Effect of Certain Breakfasts on Appetite Control N/A
Completed NCT02379312 - Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams N/A
Completed NCT03697486 - The Effect of Breakfast With Different Macronutrient Composition on PYY, Ghrelin, GLP-1,Glucose Level, VAS for Hunger, VAS for Satiety and Ad Libitum Intake 4 Hours After Breakfast in Obese Women N/A
Completed NCT03701503 - The Comparison of PYY, Ghrelin, GLP1, Glucose Level, Level of Satiety, and Ad Libitum Intake in Obese and Non-Obese Patients After Breakfast With Balanced Macronutrient Composition N/A
Completed NCT01222845 - Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge N/A
Completed NCT03900130 - The Omnibus Satiety Metric: Predicting Satiety in Humans Through Brain, Blood, and Subjective Data N/A
Completed NCT05012046 - Effect of 100% Orange Juice on Food Intake and Glycemic Response in Adults N/A
Completed NCT02484625 - The Effect of Dairy and Non-Dairy Snacks on Food Intake, Subjective Appetite in Children N/A
Withdrawn NCT01246492 - The Effect of Artificial Sweeteners on Blood Glucose Response N/A
Completed NCT05534152 - Effect of Sumac on Appetite and Food Intake N/A
Completed NCT03974165 - Cereal-based Products Fortified With Legumes and Effects on Glycemic Control and Appetite Regulation N/A
Completed NCT01592149 - Survey of Prevalence of Loss of Appetite in Subject With Health Disorders N/A
Recruiting NCT01121783 - The Effect of Lactisole on the Responses to Glucose Solution N/A
Completed NCT01102907 - Effect of Food Form on Satiety and Gastric Emptying
Completed NCT03128684 - The Effects of Lentil-containing Food Products on Satiety and Food Intake N/A